Therapeutic Peptide Pipeline

About Dia Beta Labs

Dia Beta Labs is a private, preclinical-stage biotech targeting the root cause of Type 2 Diabetes progression through a novel peptide platform. The company's pipeline, derived from over three decades of academic research, is designed to protect, improve function in, and increase the mass of pancreatic beta-cells. Operating in the massive and growing diabetes and obesity market, Dia Beta Labs seeks to fill a critical unmet need for disease-modifying therapies that can prevent debilitating complications. Its strategy leverages a seasoned team with deep expertise in diabetes research and drug development.

Therapeutic Areas

Other Type 2 Diabetes / Metabolic Disease Drugs